MYC and Burkitt lymphoma: In recent years, high-resolution genomic analyses have demonstrated that other genetic alterations, such as gain-of-function mutations in TCF3 and inactivating mutations in ID3 (the negative regulator of TCF3) and in CNND3, cooperate with MYC in BL pathogenesis [90,91,92] (Figure 3).